Risk factor
High price volatility
Profitability factor
Greatly overvalued vs peers
About
Improve Medical Instruments Co., Ltd. operates as an international supplier, delivering advanced technologies, medical products, and critical services to clinical laboratories and for patient care, spanning both the Chinese market and global regions. A significant portion of its product portfolio comprises leading brands such as IMPROVACUTER evacuated blood collection systems, IMPROMINI capillary blood collection systems, IMPROSWAB microbiological transport systems, IMPRONURSE infusion and syringe pumps, and LONGX urine analysis platforms, alongside an assortment of in-vitro diagnostic reagents. Furthermore, the company's comprehensive offerings extend to a wide range of ancillary equipment and disposables, including blood collection needles, pulsewave blood pressure monitors, thrombosis viscoelastic analysis systems, feces analysis systems, automated blood and urine collection tube preparation systems, graphical user interface (GUI) devices, intelligent sorting units, multi-functional blood collection workstations, smart queue management systems, automatic tube packing systems, and consumable labels. Originally incorporated in 1996 as Guangzhou Improve Medical Instruments Co., Ltd., the enterprise maintains its headquarters in Guangzhou, China.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,